30 July 2018 - - Hyderabad, India-based integrated pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Hervycta (trastuzumab), a biosimilar of Roche's Herceptin, in India, indicated for the treatment of HER2-positive cancers, the company said.
Dr. Reddy's Hervycta is available in strengths of 150mg and 440mg multiple dose vials.
Dr. Reddy's currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.
Biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product.
Dr. Reddy's is committed to providing affordable and innovative medicines through its three businesses - pharmaceutical services and active ingredients, global generics, and proprietary products.
The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe, including the US, India, Russia and CIS countries, and Europe.